ASND Annual CFF
$145.39 M
-$273.05 M-65.25%
31 December 2023
Summary:
As of January 23, 2025, ASND annual cash flow from financing activities is $145.39 million, with the most recent change of -$273.05 million (-65.25%) on December 31, 2023. During the last 3 years, it has fallen by -$542.86 million (-78.88%). ASND annual CFF is now -78.88% below its all-time high of $688.24 million, reached on December 31, 2020.ASND Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ASND Quarterly CFF
N/A
01 September 2024
Summary:
ASND quarterly cash flow from financing activities is not available.ASND Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ASND TTM CFF
N/A
01 September 2024
Summary:
ASND TTM cash flow from financing activities is not available.ASND TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ASND Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -65.3% | - | - |
| 3 y3 years | -78.9% | - | - |
| 5 y5 years | -39.4% | - | - |
ASND Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -65.3% | at low | ||||
| 5 y | 5-year | -78.9% | at low | ||||
| alltime | all time | -78.9% | >+9999.0% |
Ascendis Pharma A/S Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2024 | - | $20.01 M(-369.6%) | $166.15 M(+14.3%) |
| Dec 2023 | $145.39 M(-65.3%) | -$7.42 M(-104.8%) | $145.39 M(-15.9%) |
| Sept 2023 | - | $156.09 M(-6271.3%) | $172.90 M(-2923.4%) |
| June 2023 | - | -$2.53 M(+235.5%) | -$6.12 M(-78.6%) |
| Mar 2023 | - | -$754.00 K(-103.8%) | -$28.62 M(-106.8%) |
| Dec 2022 | $418.44 M(+0.6%) | $20.09 M(-187.6%) | $418.43 M(+11.4%) |
| Sept 2022 | - | -$22.94 M(-8.4%) | $375.47 M(-55.1%) |
| June 2022 | - | -$25.03 M(-105.6%) | $835.33 M(-3.1%) |
| Mar 2022 | - | $446.31 M(-2051.1%) | $862.04 M(+107.3%) |
| Dec 2021 | $415.75 M(-39.6%) | -$22.87 M(-105.2%) | $415.75 M(-4.2%) |
| Sept 2021 | - | $436.93 M(>+9900.0%) | $434.19 M(-36.3%) |
| June 2021 | - | $1.68 M(+6856.0%) | $681.50 M(-1.2%) |
| Mar 2021 | - | $24.10 K(-100.5%) | $689.50 M(+0.2%) |
| Dec 2020 | $688.24 M(+24.6%) | -$4.44 M(-100.6%) | $688.24 M(-1.8%) |
| Sept 2020 | - | $684.23 M(+6968.6%) | $701.16 M(+5019.4%) |
| June 2020 | - | $9.68 M(-885.3%) | $13.70 M(+91.4%) |
| Mar 2020 | - | -$1.23 M(-114.5%) | $7.16 M(-98.7%) |
| Dec 2019 | $552.58 M(+130.2%) | $8.48 M(-362.4%) | $552.58 M(+0.7%) |
| Sept 2019 | - | -$3.23 M(-202.9%) | $548.84 M(+0.1%) |
| June 2019 | - | $3.14 M(-99.4%) | $548.22 M(+1.1%) |
| Mar 2019 | - | $544.19 M(>+9900.0%) | $542.31 M(+125.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | $240.02 M(+69.9%) | $4.74 M(-223.1%) | $240.02 M(-3.7%) |
| Sept 2018 | - | -$3.85 M(+39.2%) | $249.21 M(-34.4%) |
| June 2018 | - | -$2.77 M(-101.1%) | $379.67 M(-0.7%) |
| Mar 2018 | - | $241.90 M(+1636.1%) | $382.46 M(+170.8%) |
| Dec 2017 | $141.25 M(+8.6%) | $13.93 M(-89.0%) | $141.25 M(-45.0%) |
| Sept 2017 | - | $126.61 M(>+9900.0%) | $256.60 M(+97.2%) |
| June 2017 | - | $22.50 K(-96.7%) | $130.13 M(-0.4%) |
| Mar 2017 | - | $686.00 K(-99.5%) | $130.69 M(+0.5%) |
| Dec 2016 | $130.00 M(+10.8%) | $129.29 M(>+9900.0%) | $130.00 M(>+9900.0%) |
| Sept 2016 | - | $137.00 K(-76.3%) | $541.60 K(-88.2%) |
| June 2016 | - | $577.30 K(>+9900.0%) | $4.58 M(+57.5%) |
| Mar 2016 | - | $0.00(-100.0%) | $2.91 M(-97.5%) |
| Dec 2015 | $117.34 M(+84.2%) | -$172.70 K(-104.1%) | $117.34 M(-35.4%) |
| Sept 2015 | - | $4.18 M(-481.5%) | $181.76 M(+2.7%) |
| June 2015 | - | -$1.09 M(-101.0%) | $177.05 M(-0.6%) |
| Mar 2015 | - | $114.43 M(+78.1%) | $178.14 M(+179.6%) |
| Dec 2014 | $63.71 M(<-9900.0%) | $64.24 M(<-9900.0%) | $63.71 M(<-9900.0%) |
| Sept 2014 | - | -$535.40 K(<-9900.0%) | -$535.40 K(<-9900.0%) |
| June 2014 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2014 | - | $0.00 | $0.00 |
| Dec 2013 | -$292.20 K(+10.8%) | - | - |
| Dec 2012 | -$263.60 K | - | - |
FAQ
- What is Ascendis Pharma A/S annual cash flow from financing activities?
- What is the all time high annual CFF for Ascendis Pharma A/S?
- What is Ascendis Pharma A/S annual CFF year-on-year change?
- What is the all time high quarterly CFF for Ascendis Pharma A/S?
- What is the all time high TTM CFF for Ascendis Pharma A/S?
What is Ascendis Pharma A/S annual cash flow from financing activities?
The current annual CFF of ASND is $145.39 M
What is the all time high annual CFF for Ascendis Pharma A/S?
Ascendis Pharma A/S all-time high annual cash flow from financing activities is $688.24 M
What is Ascendis Pharma A/S annual CFF year-on-year change?
Over the past year, ASND annual cash flow from financing activities has changed by -$273.05 M (-65.25%)
What is the all time high quarterly CFF for Ascendis Pharma A/S?
Ascendis Pharma A/S all-time high quarterly cash flow from financing activities is $684.23 M
What is the all time high TTM CFF for Ascendis Pharma A/S?
Ascendis Pharma A/S all-time high TTM cash flow from financing activities is $862.04 M